Relationships between flavin‐containing mono‐oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population
Open Access
- 13 September 2013
- journal article
- pharmacogenetics
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 77 (5) , 839-851
Abstract
Aim: The aim of this study was to investigate relationships between flavin‐containing mono‐oxygenase 3 (FMO3) genotype and phenotype (conversion of odorous trimethylamine into non‐odorous trimethylamine N‐oxide) in a large Japanese cohort suffering from trimethylaminuria.Methods: Urinary excretion of trimethylamine and trimethylamine N‐oxide was determined for 102 volunteers with self‐reporting symptoms of trimethylaminuria. For each we determined the sequence of the entire coding region, plus 1.3 kb of flanking intronic and 2.5 kb of the upstream region of the FMO3 gene. The affect of upstream variants on transcription was determined with a reporter gene assay.Results: Seventy‐eight subjects were diagnosed as suffering from trimethylaminuria, based on urinary excretion of N‐oxide. Of these, 13 were classified as severe, 56 as moderate and nine as mild cases, excreting N‐oxide, respectively. Twenty‐seven mutations were identified in FMO3, 15 in the coding region, of which eight abolish or severely impair FMO3 activity (Pro70Leu, Cys197fsX, Thr201Lys, Arg205Cys, Met260Val, Trp388Ter, Gln470Ter and Arg500Ter), and 12 in the upstream region. The mutations segregate into 19 haplotypes, including four different combinations of upstream mutations, each of which reduces transcriptional activity in comparison with the ancestral upstream sequence of FMO3.Conclusions: Comparisons of genotype and phenotype reveal that severe trimethylaminuria is caused by loss of function mutations in FMO3. For moderate and mild cases the situation is more complex, with most resulting from factors other than FMO3 genotype. Our results have implications for the diagnosis and management of the disorder.Keywords
This publication has 48 references indexed in Scilit:
- Clinical utility gene card for: TrimethylaminuriaEuropean Journal of Human Genetics, 2011
- Developmental variations in metabolic capacity of flavin‐containing mono‐oxygenase 3 in childhoodBritish Journal of Clinical Pharmacology, 2010
- Hepatic Flavin-Containing Monooxygenase Gene Regulation in Different Mouse Inflammation ModelsDrug Metabolism and Disposition, 2009
- Flavin-containing monooxygenases: mutations, disease and drug responseTrends in Pharmacological Sciences, 2008
- Diagnosis and management of trimethylaminuria (FMO3 deficiency) in childrenJournal of Inherited Metabolic Disease, 2006
- Flavin-containing monooxygenase activity can be inhibited by nitric oxide-mediated S-nitrosylationLife Sciences, 2004
- Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patientsLife Sciences, 2004
- Haplotype reconstruction from genotype data using Imperfect PhylogenyBioinformatics, 2004
- Trimethylamine and Foetor HepaticusScandinavian Journal of Gastroenterology, 1999
- The molecular biology of the flavin-containing monooxygenases of manChemico-Biological Interactions, 1995